Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

SK Bioscience (302440 KS): Murky Outlook On Weak Vaccine Demand And Flooding Supply

SKC Co: Announces a Share Buyback of 5% of Outstanding Shares

Alpha Generation Through Share Buybacks in Korea: October 2022

SK Bioscience IPO Preview - Biggest IPO in Korea in 1Q 2021

Metrica Partners Urges SK Chemicals to Partially Sell SK Bioscience & Pay Higher Dividends

SK Chemicals - Its Market Cap Is Only 19% of Its Stake in SK Bioscience

SK Bioscience: Stock Price Up 393% Since IPO & 6 Months Lockup Period Ending in 1 Month

Event-Driven

<ul>
<li>After the market close on 21 April, it was reported that SK Chemical's CEO Jeon Kwang-Hyun sold all his shares (21,852 shares) of SK Bioscience from April 19th to 21st.</li>
<li>The fact that the CEO of SK Chemical, the controlling shareholder of SK Bioscience, sold all his stake in the latter company does not bode well for SK Bioscience. </li>
<li>The CEO of SK Chemical selling all his shares in SK Bioscience and increasing reluctance in getting more COVID booster shots suggest further downside risk for SK Bioscience. </li>
</ul>


After the market close on 21 April, it was reported that SK Chemical's CEO Jeon Kwang-Hyun sold all his shares (21,852 shares) of SK Bioscience from April 19th to 21st.
The fact that the CEO of SK Chemical, the controlling shareholder of SK Bioscience, sold all his stake in the latter company does not bode well for SK Bioscience. 
The CEO of SK Chemical selling all his shares in SK Bioscience and increasing reluctance in getting more COVID booster shots suggest further downside risk for SK Bioscience. 


SK Chemical's CEO Sells All His Shares of SK Bioscience